1 |
Alan E, Kerry Z, Sevin G. Molecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugs. Fundam Clin Pharmacol 2022. [PMID: 36576325 DOI: 10.1111/fcp.12861] [Reference Citation Analysis]
|
2 |
Campos-peña V, Pichardo-rojas P, Sánchez-barbosa T, Ortíz-islas E, Rodríguez-pérez CE, Montes P, Ramos-palacios G, Silva-adaya D, Valencia-quintana R, Cerna-cortes JF, Toral-rios D. Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease. IJMS 2022;23:12092. [DOI: 10.3390/ijms232012092] [Reference Citation Analysis]
|
3 |
Jamshidnejad-tosaramandani T, Kashanian S, Al-sabri MH, Kročianová D, Clemensson LE, Gentreau M, Schiöth HB. Statins and cognition: Modifying factors and possible underlying mechanisms. Front Aging Neurosci 2022;14:968039. [DOI: 10.3389/fnagi.2022.968039] [Reference Citation Analysis]
|
4 |
Vallés AS, Barrantes FJ. Dendritic spine membrane proteome and its alterations in autistic spectrum disorder. Membrane Proteins 2022. [DOI: 10.1016/bs.apcsb.2021.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Vallés AS, Barrantes FJ. Dysregulation of Neuronal Nicotinic Acetylcholine Receptor-Cholesterol Crosstalk in Autism Spectrum Disorder. Front Mol Neurosci 2021;14:744597. [PMID: 34803605 DOI: 10.3389/fnmol.2021.744597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
6 |
Vallés AS, Barrantes FJ. Nanoscale Sub-Compartmentalization of the Dendritic Spine Compartment. Biomolecules 2021;11:1697. [PMID: 34827695 DOI: 10.3390/biom11111697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
7 |
Paz ML, Barrantes FJ. Cholesterol in myasthenia gravis. Arch Biochem Biophys 2021;701:108788. [PMID: 33548213 DOI: 10.1016/j.abb.2021.108788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|